4//SEC Filing
Stehman-Breen Catherine 4
Accession 0001209191-22-041343
CIK 0001818794other
Filed
Jul 5, 8:00 PM ET
Accepted
Jul 6, 6:23 PM ET
Size
5.6 KB
Accession
0001209191-22-041343
Insider Transaction Report
Form 4
Stehman-Breen Catherine
Director
Transactions
- Award
Stock Option (right to buy)
2022-07-05+7,222→ 7,222 totalExercise: $5.54Exp: 2030-07-30→ Common Stock (7,222 underlying)
Footnotes (1)
- [F1]The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved.
Documents
Issuer
Dyne Therapeutics, Inc.
CIK 0001818794
Entity typeother
Related Parties
1- filerCIK 0001702233
Filing Metadata
- Form type
- 4
- Filed
- Jul 5, 8:00 PM ET
- Accepted
- Jul 6, 6:23 PM ET
- Size
- 5.6 KB